-  Prior malignancy, except for curatively treated basal cell carcinoma of the skin and<br/>             in situ carcinoma of the cervix.<br/><br/>          -  Overexpression of HER-2, defined as IHC 3+ or IHC 2+ and FISH positive.<br/><br/>          -  Known hypersensitivity against 5-FU, leukovorin, oxaliplatin or other platinum<br/>             compounds or pazopanib.<br/><br/>          -  History or clinical evidence of central nervous system (CNS) metastases or<br/>             leptomeningeal carcinomatosis.<br/><br/>          -  Clinically significant gastrointestinal abnormalities that may increase the risk for<br/>             gastrointestinal bleeding or the absorption of investigational product<br/><br/>          -  Presence of uncontrolled infection.<br/><br/>          -  Corrected QT interval (QTc) > 480 ms using Bazett's formula.<br/><br/>          -  History of any one or more of the following cardiovascular conditions within the past<br/>             6 months: cardiac angioplasty or stenting, myocardial infarction, unstable angina,<br/>             coronary artery bypass graft surgery, symptomatic peripheral vascular disease, NYHA<br/>             III or IV congestive heart failure.<br/><br/>          -  Poorly controlled hypertension.<br/><br/>          -  History of cerebrovascular accident including transient ischemic attack (TIA),<br/>             pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6<br/>             months.<br/><br/>          -  Prior major surgery or trauma within 28 days prior to first dose of study drug and/or<br/>             presence of any non-healing wound, fracture, or ulcer.<br/><br/>          -  Evidence of active bleeding or bleeding diathesis.<br/><br/>          -  Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels.<br/><br/>          -  Hemoptysis in excess of 2.5 ml within 8 weeks of first dose of study drug.<br/><br/>          -  Any serious and/or unstable pre-existing medical, psychiatric, or other condition<br/>             that could interfere with subject's safety, provision of informed consent, or<br/>             compliance to study procedures.<br/><br/>          -  Unable or unwilling to discontinue use of prohibited medications for at least 14 days<br/>             or five half-lives of a drug (whichever is longer) prior to the first dose of study<br/>             drug and for the duration of the study.<br/><br/>          -  Treatment with any of the following anti-cancer therapies: radiation therapy, surgery<br/>             or tumor embolization within 14 days prior to the first dose of pazopanib OR<br/>             chemotherapy, immunotherapy, biologic therapy, investigational therapy or hormonal<br/>             therapy within 14 days or five half-lives of a drug (whichever is longer) prior to<br/>             the first dose of pazopanib. A neoadjuvant or adjuvant chemotherapy must be finished<br/>             at least 6 month before study entry.<br/><br/>          -  Any ongoing toxicity from prior anti-cancer therapy that is >Grade 1 and/or that is<br/>             progressing in severity, except alopecia.<br/><br/>          -  Grade 3 or 4 diarrhea.<br/><br/>          -  Peripheral polyneuropathy > NCI Grade.<br/><br/>          -  Pregnant or lactating women.<br/><br/>          -  Men or women who are planning a pregnancy within the next six months.<br/><br/>          -  Participation in another clinical trial with investigational agents within the last<br/>             30 days prior to study start.<br/><br/>          -  The patient is a colleague or employed by the study investigator or by an involved<br/>             institution including the sponsor of the study.<br/><br/>          -  Patient is detained in a psychiatric unit or imprisoned.<br/>